Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Rating of “Buy” by Brokerages
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) has received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target […]
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) has received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target […]
